First Trust Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

First Trust Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,731	Closed	-$559K	–	2519
2023 Q2	$559K	Buy	28,731 +359	+1%	+$8.52K	﹤0.01%	2111
2023 Q1	$805K	Buy	28,372 +2,113	+8%	+$62.7K	﹤0.01%	2022
2022 Q4	$768K	Sell	26,259 -1,891	-7%	-$60.1K	﹤0.01%	2052
2022 Q3	$744K	Buy	28,150 +11,393	+68%	+$418K	﹤0.01%	2091
2022 Q2	$745K	Sell	16,757 -856	-5%	-$39.3K	﹤0.01%	2081
2022 Q1	$872K	Sell	17,613 -1,012	-5%	-$48.6K	﹤0.01%	2091
2021 Q4	$948K	Buy	18,625 +2,057	+12%	+$107K	﹤0.01%	2082
2021 Q3	$924K	Buy	+16,568	New	+$815K	﹤0.01%	2067
2019 Q1	–	Sell	-7,551	Closed	-$304K	–	2463
2018 Q4	$304K	Buy	+7,551	New	+$389K	﹤0.01%	2261
2017 Q4	–	Sell	-21,472	Closed	-$1.28M	–	2474
2017 Q3	$1.28M	Sell	21,472 -3,741	-15%	-$226K	﹤0.01%	1735
2017 Q2	$1.99M	Buy	+25,213	New	+$2.06M	0.01%	1467

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Trust Advisors's EGRX Position: Q3 2023 in Review

First Trust Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 28,731 shares — an estimated $559K sold.

First Trust Advisors first reported a position in EGRX in Q2 2017 and held it in 11 quarters. The position peaked at $1.99M in Q2 2017. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

First Trust Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
First Trust Advisors sold 28,731 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $559K.
First Trust Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 11 quarters.
First Trust Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.99M in Q2 2017.
107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.